Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03301168
Recruitment Status : Active, not recruiting
First Posted : October 4, 2017
Last Update Posted : October 25, 2019
Information provided by (Responsible Party):
Bellicum Pharmaceuticals

Brief Summary:
This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially matched family donor. The study will assess whether immune cells, called T cells, from the family donor, that are specially grown in the laboratory and given back to the patient along with the stem cell transplant can help the immune system recover faster after transplant. As a safety measure these T cells have been programmed with a self-destruct switch so that they can be destroyed if they start to react against tissues (graft versus host disease).

Condition or disease Intervention/treatment Phase
Acute Lymphoblastic Leukemia Leukemia, Acute Myeloid (AML), Child Lymphoma, Non-Hodgkin Myelodysplastic Syndromes Primary Immune Deficiency Disorder Osteopetrosis Cytopenia Hemoglobinopathy in Children Anemia, Aplastic Biological: BPX-501 T cells Drug: AP1903 Phase 1 Phase 2

Expanded Access : An investigational treatment associated with this study is no longer available outside the clinical trial.   More info ...

Detailed Description:

This is a Phase 2 extension study evaluating the safety and feasibility of BPX-501 T cells infused after partially mismatched, related, TCR alpha beta T cell depleted hematopoietic stem cell transplant (HSCT) in pediatric patients. The purpose of this clinical trial is to determine whether BPX-501 infusion can enhance immune reconstitution in those patients with hematologic disorders, with the potential for reducing the severity and duration severe acute graft versus host disease (GvHD).

The trial will also evaluate the treatment of GvHD by the infusion of dimerizer drug (AP1903/rimiducid) in those subjects who present with GVHD that does not adequately respond to standard of care therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Extension Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Actual Study Start Date : April 2014
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : February 2035

Arm Intervention/treatment
Experimental: BPX-501 T cells and AP1903

TCR alpha beta depleted graft infusion with addback of BPX-501 T cells.

AP1903: Dimerizer drug administered to subjects who present with Grade I-IV acute GVHD with inadequate response to steroids within 48 hours of treatment or mild to severe chronic GVHD with inadequate response to steroids within 7 days of treatment.

Biological: BPX-501 T cells
T cells transduced with CaspaCIDe® safety switch

Drug: AP1903
administered to inactivate BPX-501 cells in the event of GVHD
Other Name: rimiducid

Primary Outcome Measures :
  1. non-relapse/transplant related mortality (TRM/NRM) [ Time Frame: 1 year ]
    To maintain the cumulative incidence of non-relapse/transplant related mortality (TRM/NRM) at 1 year in subjects given the MTD defined during the Phase I portion of the study comparable to that of a historical cohort of subjects given the alpha/beta T-cell depleted HSCT without any T-cell add-back (i.e., below 10%)

Secondary Outcome Measures :
  1. Disease-free survival [ Time Frame: 2 years ]
    Disease-free survival rates after transplantation

  2. Relapse [ Time Frame: 1 year ]
    Cumulative incidence of relapse

  3. acute GVHD [ Time Frame: 1 year ]
    Cumulative incidence and severity of acute GVHD

  4. chronic GVHD [ Time Frame: 2 years ]
    Cumulative incidence and severity of chroonic GVHD

  5. Kinetics of donor cell engraftment [ Time Frame: 3 times per week after transplant until the neutrophil count reaches 0.5 x 10E9/L. Thereafter, at least 2 times per week until the neutrophil count is > 1.0 x 10E9/L and platelets > 100 x 10E9/L. ]
    time to hematopoietic recovery defined as: neutrophils > 0.5 x 10E9/L for 3 consecutive days together with platelet count > 20 x 10E9/L and without platelet support for 7 consecutive days

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Month to 26 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age > 1 month and < 26 years
  2. Life expectancy > 10 weeks
  3. Subjects deemed eligible for allogeneic stem cell transplantation.
  4. Subjects with life-threatening hematological malignancies (high-risk ALL in 1st CR, ALL in 2nd or subsequent CR, AML in 1st CR, AML in 2nd or subsequent CR, myelodysplastic syndromes, non-Hodgkin lymphomas in 2nd or subsequent CR, other hematologic malignancies eligible for stem cell transplantation per institutional standard);
  5. Non-malignant disorders amenable to cure by an allograft:

    1. primary immune deficiencies,
    2. severe aplastic anemia not responding to immune suppressive therapy,
    3. osteopetrosis,
    4. hemoglobinopathies, (thalassemias, and sickle cell anemia, and Diamond-Blackfan anemia among others)
    5. congenital/hereditary cytopenia, including Fanconi Anemia before any clonal malignant evolution (MDS, AML) Note: Subjects will be eligible if they meet either item 4 OR item 5.
  6. Lack of suitable conventional donor (HLA identical sibling or HLA phenotypically identical relative or 10/10 unrelated donor evaluated using high resolution molecular typing) or presence of rapidly progressive disease not permitting time to identify an unrelated donor
  7. A minimum genotypic identical match of 5/ 10 is required.
  8. The donor and recipient must be identical, as determined by high resolution typing, at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA- DRB1 and HLA-DQB1.
  9. Lansky/Karnofsky score > 50
  10. Signed written informed consent

Exclusion Criteria:

  1. 1. Greater than Grade II acute GVHD or chronic extensive GVHD due to a previous allograft at the time of inclusion
  2. Subject receiving an immunosuppressive treatment for GVHD treatment due to a previous allograft at the time of inclusion
  3. Dysfunction of liver (ALT/AST > 5 times normal value, or bilirubin > 3 times normal value), or of renal function (creatinine clearance < 30 mL / min)
  4. Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or left ventricular ejection fraction < 40%)
  5. Current active infectious disease (including positive HIV serology or viral RNA)
  6. Serious concurrent uncontrolled medical disorder
  7. Pregnant or breastfeeding subject
  8. For subjects who have received more than 1 x 10E5 alpha/beta T cells/kg with the graft infusion the clinical trial site must contact the sponsor for approval to be eligible to receive BPX-501 infusion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03301168

Layout table for location information
United States, California
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027
Stanford University; Division of Pediatric Stem Cell Transplant & Regenerative Medicine
Palo Alto, California, United States, 94304
United States, District of Columbia
Children's National Medical Center
Washington, District of Columbia, United States, 20010
United States, Georgia
Children's Healthcare of Atlanta
Atlanta, Georgia, United States, 30322
United States, Massachusetts
Dana-Farber Boston Children's Cancer and Blood Disorders Center
Boston, Massachusetts, United States, 02215
United States, New York
Children's Hospital at Montefiore
Bronx, New York, United States, 10467
United States, Oregon
Oregon Health Sciences University - Doernbecher Children's Hospital
Portland, Oregon, United States, 97239
United States, Texas
University of Texas Southwestern-Children's Medical Center
Dallas, Texas, United States, 77390
Baylor College of Medicine/ Texas Children's Hospital
Houston, Texas, United States, 77030
United States, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109
Sponsors and Collaborators
Bellicum Pharmaceuticals
Layout table for investigator information
Principal Investigator: Neena Kapoor, MD Children's Hospital of LA

Layout table for additonal information
Responsible Party: Bellicum Pharmaceuticals Identifier: NCT03301168    
Other Study ID Numbers: BP-U-004
First Posted: October 4, 2017    Key Record Dates
Last Update Posted: October 25, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Bellicum Pharmaceuticals:
hematologic neoplasms
hematologic malignancies
primary immune deficiences
allogeneic stem cell transplant
Additional relevant MeSH terms:
Layout table for MeSH terms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma, Non-Hodgkin
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Anemia, Aplastic
Immunologic Deficiency Syndromes
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Leukemia, Lymphoid
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Genetic Diseases, Inborn
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Leukemia, Myeloid